Asahi Kasei-backed Veloxis Pharmaceuticals to acquire AiCuris for €780m.

Asahi Kasei-backed Veloxis Pharmaceuticals, a developer of specialty pharmaceutical therapies and programs, agreed to acquire AiCuris, a developer of antiviral therapeutics aimed at treating infections in immunocompromised patients, for €780m. “Asahi Kasei’s goal to address serious unmet needs in infectious diseases aligns with our mission to provide innovative antiviral therapies for immunocompromised patients. This transaction recognizes the strength of our R&D engine and the strategic progress our team has achieved with PREVYMIS®, pritelivir and AIC468. Becoming part of Asahi Kasei will accelerate our research and development, strengthen launch readiness in the US, and bring our programs to more patients worldwide. I am deeply grateful to our employees, partners and investors, and the patients who gave us their trust, leading to this successful outcome,” Larry Edwards, Aicuris CEO.